ALK and non-small cell lung carcinoma: An accurate and validated ALK assay is necessary for the selection of ALK-positive NSCLC patients (see section 5.1). ALK-positive NSCLC status should be established prior to initiation of Zykadia therapy. Assessment for ALK-positive NSCLC should be performed by laboratories with demonstrated proficiency in the specific technology being utilised.